Verrica Pharmaceuticals' Lead Product, Ycanth, Has Received New Chemical Entity Status And A Listing In The Orange Book From The FDA, Providing A Minimum of Five Years Of Regulatory Exclusivity
Portfolio Pulse from Benzinga Newsdesk
Verrica Pharmaceuticals' lead product, YCANTH, has been granted New Chemical Entity (NCE) status and listed in the FDA's Orange Book, ensuring at least five years of regulatory exclusivity. The company's U.S. patents for YCANTH are expected to expire between 2034 and 2041, potentially extending exclusivity further.
March 26, 2024 | 11:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Verrica Pharmaceuticals' YCANTH granted NCE status and Orange Book listing, ensuring regulatory exclusivity until at least 2028, with patents extending potentially until 2041.
The granting of NCE status and Orange Book listing to YCANTH by the FDA is a significant positive development for Verrica Pharmaceuticals. It not only provides a competitive edge by ensuring regulatory exclusivity for a minimum of five years but also signals confidence in the product's novelty and potential market impact. The extended patent life till between 2034 and 2041 further solidifies the company's position in the market, potentially enhancing investor confidence and positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100